A Phase IV Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma That is Not Responding to Four or More Standard Treatments or Has Come Back After Several Standard Treatments
brief summary
This is a Phase 4, multicenter, open-label, single-arm study evaluating the safety and efficacy of elranatamab monotherapy in adult participants with relapsed or refractory multiple myeloma in India. Eligible participants must have received at least four prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody. All enrolled participants will receive elranatamab; there is no comparator or control arm. Approximately 100 participants are planned to be enrolled across approximately 10 study sites in India. Study assessments will include evaluation of disease response and monitoring of adverse events in accordance with the study protocol.
detailed description
This Phase 4, multicenter, open-label, single-arm study is being conducted in India following approval of elranatamab by the Central Drugs Standard Control Organization (CDSCO). The study is intended to fulfill a post-approval requirement and further characterize the safety and efficacy of elranatamab in Indian patients with relapsed or refractory multiple myeloma. The study plans to enroll approximately 100 participants across approximately 10 sites in India.
The study population consists of adult patients in India with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody, and who have demonstrated disease progression on their last therapy.
Participants who meet the eligibility criteria will enter an open-label treatment phase and receive elranatamab monotherapy. Elranatamab will be administered using a step-up dosing regimen consisting of 12 mg on Day 1 and 32 mg on Day 4, followed by a full treatment dose of 76 mg once weekly from Week 2 through Week 24. For participants who have received at least 24 weeks of treatment and achieved a response, the dosing interval will transition to once every 2 weeks. Subsequently, if the response is maintained, the dosing interval may be extended to once every 4 weeks after Cycle 13 Day 1 based on the investigator's judgment.
Study assessments will be performed according to the Schedule of Activities and will include evaluation of disease response, safety monitoring, and collection of study-specific clinical data. There is no comparator or control arm.
Following completion or discontinuation of study treatment, participants will undergo an End-of-Treatment (EOT) visit, anticipated to occur approximately 12 months after enrollment. Participants will subsequently complete a safety follow-up visit approximately 3 months after the last dose of study treatment. The study will further characterize the safety profile and clinical outcomes associated with elranatamab monotherapy in participants with relapsed or refractory multiple myeloma in India.
official title
A PHASE-4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY EVALUATING ELRANATAMAB AS MONOTHERAPY IN ADULT PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA IN INDIA, WITH AT LEAST FOUR PRIOR THERAPIES, INCLUDING AN IMMUNOMODULATORY AGENT, A PROTEASOME INHIBITOR AND AN ANTI-CD38 ANTIBODY